A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Recruiting · NCT06046495 · Registry updated 2025-04-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2025-04-23 | NCT06046495 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Avistone Biotechnology Co., Ltd. | 13 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Nebraska Cancer Specialists | Omaha | United States | 40 |
| Sarah Cannon Research Institute | Nashville | United States | 119 |
| Swedish Health Sciences | Seattle | United States | 1 |
| University of California-Davis | Sacramento | United States | 1 |